BiotechTube
TrippBio

TrippBio

Boston, United States· Est.
trippbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

TrippBio is a clinical-stage biotech leveraging drug repurposing to develop host-targeted antiviral therapies for respiratory diseases. Its lead asset, PanCytoVir™ (oral probenecid), has demonstrated positive Phase 2 results in COVID-19 and is being advanced for influenza, with a strategy targeting multiple viruses like RSV. The company is led by an experienced team with deep drug development expertise and operates as a private, pre-revenue entity aiming to bring life-saving treatments to market efficiently.

Infectious DiseaseRespiratory

Technology Platform

Host-targeted antiviral therapy through repurposing of existing drugs with known safety profiles, focusing on inhibiting host cell pathways essential for viral replication and modulating inflammation.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The large and persistent global market for influenza and respiratory antivirals presents a major opportunity.
PanCytoVir's dual antiviral/anti-inflammatory mechanism and resistance-resistant profile could differentiate it from current standards of care.
The drug repurposing strategy enables faster, lower-cost development with a known safety base.

Risk Factors

Key risks include failure in later-stage clinical trials for influenza, inability to secure sufficient funding as a private company, and intense competition from established and novel antiviral therapies.
Regulatory hurdles and market adoption for a repurposed drug also pose significant challenges.

Competitive Landscape

TrippBio competes in the crowded antiviral space, facing off against approved drugs like oseltamivir (Tamiflu) and baloxavir (Xofluza) for influenza, and Paxlovid for COVID-19. Its competitive edge hinges on demonstrating superior efficacy, a dual mechanism of action, and a high barrier to resistance through host-targeting.

More companies in Small Molecule Drugs →More companies in United States →